Ryan Livingston

Arrowhead's ARO-DIMER-PA cut PCSK9 by 72% and APOC3 by 88% with single doses, driving LDL-C and triglyceride reductions in mixed hyperlipidemia.

The novel cardiac sarcomere modulator from Edgewise Therapeutics saw substantial improvements in both nonobstructive and obstructive HCM after 12 weeks.

Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.

Catch up on any stroke-related news you may have missed during 4 action-packed days of presentations and trial readouts at ESC 2026.

Catch up on data from some of the most impactful trials presented at the European Society of Cardiology Congress 2026.

Abbott's dual-energy PFA/RF ablation catheter met its primary effectiveness and safety endpoints in the 12-month FlexPulse IDE study behind its FDA nod.

The investigational therapy did not achieve statistical significance in KCCQ-TSS or in 6MWD, but saw substantial changes in exploratory secondary endpoints.

Despite failing to display a clinically significant reduction in all-cause death or hospitalization for cardiovascular events, the trial did highlight evolocumab’s LDL-C-lowering capacity.

A new study has indicated the correlation between EHT and atrial myopathy, which in turn contributes to potential ischemic stroke incidence.

The updated ESC guidelines make sweeping changes to HF terminology, eliminating HFmrEF and recategorizing acute HF for patients with slower symptom development.

Both apixaban and rivaroxaban resulted in improved risk of stroke, systemic embolism, major bleeding, and cardiovascular death compared to no anticoagulation.

Abbott's Libre Duo 10 Day earned FDA De Novo authorization, becoming the first continuous dual glucose-ketone monitor for diabetes.

United Therapeutics' ralinepag NDA rests on phase 3 ADVANCE OUTCOMES data showing a 55% reduction in clinical worsening versus placebo.

A new study from the AHA has indicated the real prevalence of CKM syndrome stages 0-3 in young adults in their 20s.

A recent study has shown that a significantly greater proportion of patients with HF were correctly identified when testing NT-proBNP levels.

A recent secondary analysis of the HELIOS-B trial has highlighted vutrisiran’s effects on atrial myopathy in patients with ATTR-CM.

The phase 3 trial showed a 55% reduction in Level 2 and Level 3 hypoglycemic events versus placebo, meeting all secondary endpoints.

The FDA approved a single-use autoinjector for lerodalcibep-liga alongside an updated lerodalcibep-liga indication reflecting MACE risk reduction from LDL-C lowering with statins or add-on PCSK9 inhibitors.

Novo Nordisk's once-weekly insulin icodec-abae (Awiqli) has launched nationwide for adults with type 2 diabetes.

Get ahead of the curve with the top 6 trials to watch ahead of ESC 2026.

Phase 3 LEVEL trial of TNX-103 missed its primary 6MWD endpoint in PH-HFpEF, though a sicker patient subgroup showed benefit versus placebo.

In a trial comparing tirzepatide initiation with sitagliptin, the GLP-1/glucose dual agonist displayed greater reductions in major cardiovascular events.

Examining individual pregnancy outcomes rather than defining women by the presence or absence of complications more reliably predicts later CVD death.

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

July saw some of the biggest FDA approvals so far in 2026 – catch up on what you might have missed!

A recent study from Kaiser Permanente has indicated substantial HbA1c improvements among patients receiving food-based support.

All cardiovascular disease risks decreased proportionately across all quintiles of diet consistency, according to recent data.

The ACC's new decision pathway incorporates SGLT2 inhibitor finerenone and data on incretin therapy into HFpEF diagnosis and management guidance.